Aimmune Therapeutics, Inc. (AIMT) [Rocket]

In millions, except per share items	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15	Dec-31-14	Dec-31-13
	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Total revenues	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cost of goods sold	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross profit	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Selling, general and administrative [+]	125.8	81.9	43.9	26.9	16.2	3.0	1.3
General and administrative	125.8	81.9	43.9	26.9	16.2	3.0	1.3
Research and development	124.0	133.4	89.3	54.6	19.8	8.2	3.5
EBITDA [+]	-245.7	-213.7	-132.3	-81.0	-35.9	-11.1	-4.7
EBITDA growth	15.0%	61.5%	63.4%	125.7%	223.2%	133.8%
Depreciation and amortization	4.1	1.6	1.0	0.5	0.1	0.0	0.0
EBIT [+]	-249.8	-215.3	-133.3	-81.5	-36.0	-11.1	-4.8
EBIT growth	16.0%	61.6%	63.5%	126.5%	223.4%	134.0%
Interest income, net [+]	0.9	4.9	2.1	0.7			-0.1
Interest expense	4.9	0.1	0.1				0.1
Interest income	5.9	5.0	2.2	0.7
Other income (expense), net [+]	1.1	-0.2	-0.1		0.2	0.0	0.0
Other	1.1	-0.2	-0.1		0.2	0.0	0.0
Pre-tax income	-247.8	-210.7	-131.3	-80.8	-35.8	-11.1	-4.8
Income taxes	0.7	0.1	0.1	0.0	0.0	0.0	0.0
Tax rate				0.0%	0.0%	0.0%	0.0%
Net income	-248.5	-210.8	-131.3	-80.8	-35.8	-11.1	-4.8

Basic EPS [+]	($3.97)	($3.67)	($2.61)	($1.89)	($1.88)	($3.80)	($1.65)
Growth	8.2%	40.9%	37.8%	0.5%	-50.5%	130.3%
Diluted EPS [+]	($3.97)	($3.67)	($2.61)	($1.89)	($1.88)	($3.80)	($1.65)
Growth	8.2%	40.9%	37.8%	0.5%	-50.5%	130.3%

Shares outstanding (basic) [+]	62.6	57.4	50.4	42.8	19.0	2.9	2.9
Growth	9.0%	13.9%	17.9%	124.5%	550.1%	0.1%
Shares outstanding (diluted) [+]	62.6	57.4	50.4	42.8	19.0	2.9	2.9
Growth	9.0%	13.9%	17.9%	124.5%	550.1%	0.1%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.